SCHEMBL10043935

SCHEMBL10043935

Cc1cc2c(cn1)cc(-c1cc(C(=O)NC(=O)Nc3ncc(C)s3)ccc1C)c(=O)n2C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPK14 Q16539 11/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
POLB P06746 2/20 0.42
TSHR P16473 1/20 0.42
RPS6KA2 Q15349 1/20 0.39
NPC1 O15118 3/20 0.39
PAX8 Q06710 1/20 0.39
LCK P06239 2/20 0.39
KIT P10721 2/20 0.39
KDR P35968 2/20 0.39
MAPKAPK2 P49137 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK13 O15264 1/20 0.37
RAF1 P04049 1/20 0.37
PDGFRA P16234 1/20 0.37
MAPK12 P53778 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043905 0.93 RAB9A (0.55) RAB9AALDH1A1MAPK14MEN1KMT2A
SCHEMBL10043930 0.87 ALDH1A1 (0.52) RAB9AALDH1A1MAPK14MEN1KMT2A
SCHEMBL10043948 0.86 MAPK14 (0.42) RAB9AMAPK14POLBNPC1LCK
SCHEMBL10043929 0.86 MAPK14 (0.42) ALDH1A1MAPK14LCKKITKDR
SCHEMBL10043932 0.85 MAPK14 (0.43) RAB9AALDH1A1MAPK14NPC1LCK
SCHEMBL501911 0.85 SYK (0.46) RAB9AMAPK14MEN1KMT2ANPC1
SCHEMBL10043937 0.84 PTGER3 (0.51) RAB9AALDH1A1MAPK14MEN1KMT2A
SCHEMBL10043931 0.84 MAPK14 (0.47) MAPK14LCKKITKDRMAPKAPK2
SCHEMBL10043944 0.84 SRC (0.41) RAB9AALDH1A1MAPK14TSHRNPC1
SCHEMBL10043942 0.84 PCTP (0.44) RAB9AALDH1A1MAPK14MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885ALDH1A1 4274/4885MAPK14 117/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885ALDH1A1 4274/4885MAPK14 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.